Skip to main content

Table 7 Ocular adverse events over a 6-month period from pegaptanib treatment initiation.

From: Newly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review study

Adverse event

Number of subjects with occurrence

Total number of occurrences

Rate of occurrence by number of injections*

Endophthalmitis

1

1

0.003

Retinal detachment

0

0

0

Increased intraocular pressure

0

0

0

Retinal tear

0

0

0

Traumatic cataract

0

0

0

Vitreous haemorrhage

0

0

0

Geographic atrophy

2

2

0.006

Other

0

0

0

  1. * Based on 326 total injections received by study subjects.
  2. Unclear history.